{
    "id": "4dc2ec1d-ed65-481b-bc48-fae589eae213",
    "indications": {
        "text": "granisetron hydrochloride injection , serotonin-3 ( 5-ht3 ) receptor antagonist indicated : prevention nausea and/or vomiting associated initial repeat courses emetogenic cancer therapy , including high-dose cisplatin . prevention treatment postoperative nausea vomiting adults . antiemetics , routine prophylaxis recommended patients little expectation nausea and/or vomiting occur postoperatively . patients nausea and/or vomiting must avoided postoperative period , granisetron hydrochloride injection recommended even incidence postoperative nausea and/or vomiting low .",
        "doid_entities": [
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "prevention chemotherapy-induced nausea vomiting ( 2.1 ) : recommended 10 mcg/kg intravenously within 30 minutes initiation chemotherapy pediatric patients ( 2 16 years ) : recommended 10 mcg/kg prevention postoperative nausea vomiting ( 2.2 ) : recommended 1 mg , undiluted , administered intravenously 30 seconds , anesthetic induction immediately reversal anesthesia . treatment postoperative nausea vomiting ( 2.2 ) : recommended 1 mg , undiluted , administered intravenously 30 seconds .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "granisetron hydrochloride injection usp , 1 mg/ml ( free base ) , supplied 1 ml single-dose vials 4 mg/4 ml multiple-dose vials . 1 mg ( base ) per ml : single-dose vials carton 1 ndc 55150-175-01 4 mg per 4 ml ( 1 mg ( base ) /ml ) : multiple-dose vials carton 1 ndc 55150-176-04 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . discard unused portion single-dose vials . multiple-dose vial penetrated , contents used within 30 days . freeze . protect light . retain carton time . vial stopper made natural rubber latex .",
    "adverseReactions": "granisetron hydrochloride injection contraindicated patients known hypersensitivity ( e.g . , anaphylaxis , shortness breath , hypotension , urticaria ) components .",
    "ingredients": [
        {
            "name": "GRANISETRON HYDROCHLORIDE",
            "code": "318F6L70J8",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5538"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31404"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32063"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        }
    ],
    "organization": "Eugia US LLC",
    "name": "Granisetron Hydrochloride",
    "effectiveTime": "20250424",
    "indications_original": "Granisetron hydrochloride injection, \u00a0is a serotonin-3 (5-HT3) receptor antagonist indicated for:\n                  \n                  \n                     The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.\n                     The prevention and treatment of postoperative nausea and vomiting in adults. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low.",
    "contraindications_original": "Prevention of chemotherapy-induced nausea and vomiting ( 2.1 ): Recommended dosage is 10 mcg/kg intravenously within 30\u00a0minutes before initiation of chemotherapy Pediatric patients (2 to 16 years): Recommended dosage is 10\u00a0mcg/kg Prevention of postoperative nausea and vomiting ( 2.2 ): Recommended dosage is 1 mg, undiluted, administered intravenously over 30 seconds, before anesthetic induction or immediately before reversal of anesthesia. Treatment of postoperative nausea and vomiting ( 2.2 ): Recommended dosage is 1 mg, undiluted, administered intravenously over 30 seconds.",
    "warningsAndPrecautions_original": "Granisetron hydrochloride injection USP, 1 mg/mL (free base), is supplied in 1 mL Single-Dose Vials and 4 mg/4 mL Multiple-Dose Vials.\n                        \n                           \n                            1 mg (base) per mL:\n                        \n                     \n                      \u00a0\u00a0\u00a0Single-Dose Vials in a carton of 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0NDC 55150-175-01\n                        \n                           \n                            4 mg per 4 mL (1 mg (base)/mL):\n                        \n                     \n                      \u00a0\u00a0\u00a0Multiple-Dose Vials in a carton of 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 55150-176-04\n                        \n                         Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].\n                      Discard unused portion for the single-dose vials.\n                      Once the multiple-dose vial is penetrated, its contents should be used within 30 days.\n                     \n                     Do not freeze. Protect from light. Retain in carton until time of use.\n                        \n                     The vial stopper is not made with natural rubber latex.",
    "adverseReactions_original": "Granisetron hydrochloride injection is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis, shortness of breath, hypotension, urticaria) to the drug or to any of its components.",
    "drug": [
        {
            "name": "Granisetron Hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5538"
        }
    ]
}